Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical trial evaluating CUE401

Next Previous
Trial Profile

A clinical trial evaluating CUE401

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 08 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CUE 401 (Primary)
  • Indications Autoimmune disorders
  • Focus Adverse reactions

Most Recent Events

  • 08 Mar 2023 New trial record
  • 01 Mar 2023 According to a Cue Biopharma media release, the company will take part in two investor healthcare conferences in March, the Cowen 43rd Annual Health Care Conference being held in Boston, Massachusetts March 6-8, 2023, and the Oppenheimer 33rd Annual Healthcare Conference being held virtually March 13-15, 2023; the company will also discuss their newly established partnership with Ono Pharmaceutical to help advance Cue Biopharmas lead autoimmune disease asset, CUE-401, toward the clinic.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top